These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Li-Fraumeni syndrome: the genetics and treatment considerations for the sarcoma and associated neoplasms. Upton B; Chu Q; Li BD Surg Oncol Clin N Am; 2009 Jan; 18(1):145-56, ix. PubMed ID: 19056046 [TBL] [Abstract][Full Text] [Related]
6. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Vahteristo P; Tamminen A; Karvinen P; Eerola H; Eklund C; Aaltonen LA; Blomqvist C; Aittomäki K; Nevanlinna H Cancer Res; 2001 Aug; 61(15):5718-22. PubMed ID: 11479205 [TBL] [Abstract][Full Text] [Related]
7. Checkpoint gene linked to human cancer. Hagmann M Science; 1999 Dec; 286(5449):2433-4. PubMed ID: 10636795 [No Abstract] [Full Text] [Related]
8. Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Sodha N; Houlston RS; Bullock S; Yuille MA; Chu C; Turner G; Eeles RA Hum Mutat; 2002 Dec; 20(6):460-2. PubMed ID: 12442270 [No Abstract] [Full Text] [Related]
9. Polymorphic hCHK2/hCds1 codon 84 allele and risk of squamous cell carcinoma of the head and neck--a case-control analysis. Zheng Y; Li L; Shen H; Sturgis EM; Eicher SA; Strom SS; Spitz MR; Wei Q Carcinogenesis; 2001 Dec; 22(12):2005-8. PubMed ID: 11751432 [TBL] [Abstract][Full Text] [Related]
10. Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Varley J; Haber DA Breast Cancer Res; 2003; 5(3):123-5. PubMed ID: 12793891 [TBL] [Abstract][Full Text] [Related]
14. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970 [TBL] [Abstract][Full Text] [Related]
15. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Lee SB; Kim SH; Bell DW; Wahrer DC; Schiripo TA; Jorczak MM; Sgroi DC; Garber JE; Li FP; Nichols KE; Varley JM; Godwin AK; Shannon KM; Harlow E; Haber DA Cancer Res; 2001 Nov; 61(22):8062-7. PubMed ID: 11719428 [TBL] [Abstract][Full Text] [Related]
16. A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Sodha N; Houlston RS; Williams R; Yuille MA; Mangion J; Eeles RA Hum Mutat; 2002 Feb; 19(2):173-7. PubMed ID: 11793476 [TBL] [Abstract][Full Text] [Related]
17. Analysis of the CHK2 gene in lymphoid malignancies. Tavor S; Takeuchi S; Tsukasaki K; Miller CW; Hofmann WK; Ikezoe T; Said JW; Koeffler HP Leuk Lymphoma; 2001 Jul; 42(3):517-20. PubMed ID: 11699418 [TBL] [Abstract][Full Text] [Related]
18. Mutations of Chk2 in primary hematopoietic neoplasms. Hangaishi A; Ogawa S; Qiao Y; Wang L; Hosoya N; Yuji K; Imai Y; Takeuchi K; Miyawaki S; Hirai H Blood; 2002 Apr; 99(8):3075-7. PubMed ID: 11949635 [No Abstract] [Full Text] [Related]
19. p53 germline mutations in Li-Fraumeni syndrome. Santibáñez-Koref MF; Birch JM; Hartley AL; Jones PH; Craft AW; Eden T; Crowther D; Kelsey AM; Harris M Lancet; 1991 Dec; 338(8781):1490-1. PubMed ID: 1683921 [TBL] [Abstract][Full Text] [Related]
20. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes. Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]